Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Aim To evaluate the effects of canagliflozin on plasma volume, urinary glucose excretion ( UGE ), fasting plasma glucose ( FPG ), glycated haemoglobin ( HbA1c ) and additional measures of fluid/electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers. Methods Patients ( N = 36) were randomized (1 : 1) to receive canagliflozin 300 mg or...